secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2026-05-11T12:40:53+00:00
Accession:  0001213900-26-054219
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharma Q1 net loss $2M; cash $4.6M; FDA policy shift may aid AD04 path
----------------------------------------------------------------------------

- Cash $4.6M as of Mar 31, 2026, down from $5.9M at Dec 31, 2025; runway into H2 2026.
- Net loss $2.0M vs $2.2M YoY; R&D expenses down 42% to $433K; G&A up 3% to $1.6M.
- FDA signals possible single pivotal trial for AD04; bipartisan AUD legislation introduced.
- Established collaboration framework with Molteni Farmaceutici for European commercial pathway.
- International patent application published; if granted, AD04 protection extended to 2045.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390026054219/0001213900-26-054219-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390026054219/ea0289947-8k_adialpharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-054219

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer